KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) EPS (Weighted Average and Diluted) (2016 - 2025)

Regeneron Pharmaceuticals has reported EPS (Weighted Average and Diluted) over the past 16 years, most recently at $7.87 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at $7.87 for Q4 2025, down 2.96% from a year ago — trailing twelve months through Dec 2025 was $41.57 (up 8.45% YoY), and the annual figure for FY2025 was $41.48, up 8.19%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $7.87 at Regeneron Pharmaceuticals, down from $13.62 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for REGN hit a ceiling of $27.97 in Q2 2021 and a floor of $6.27 in Q1 2024.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was $10.15 (2021), compared with a mean of $11.25.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): skyrocketed 267.54% in 2021 and later crashed 73.29% in 2022.
  • Regeneron Pharmaceuticals' EPS (Weighted Average and Diluted) stood at $19.68 in 2021, then crashed by 46.7% to $10.49 in 2022, then fell by 2.76% to $10.2 in 2023, then dropped by 20.49% to $8.11 in 2024, then fell by 2.96% to $7.87 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were $7.87 (Q4 2025), $13.62 (Q3 2025), and $12.81 (Q2 2025) per Business Quant data.